A case of successful posaconazole salvage therapy for rhinocerebral mucormycosis after failure of amphotericin B.
- Author:
Woo Jae KIM
1
;
Song Yee HAN
;
Young Hee NAM
;
Jung Min KIM
;
Hee Bae AHN
;
Su Jin KIM
;
Hyuck LEE
Author Information
1. Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea. hyucklee@gmail.com
- Publication Type:Case Report
- Keywords:
Rhinocerebral mucormycosis;
Triazoles
- MeSH:
Amphotericin B;
Danazol;
Diabetes Mellitus, Type 2;
Humans;
Middle Aged;
Mucormycosis;
Salvage Therapy;
Triazoles
- From:Korean Journal of Medicine
2010;79(5):587-591
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
A 58-year-old man with uncontrolled type 2 diabetes mellitus developed rhinocerebral mucormycosis. The infection progressed to intracranial extension despite more than 5 weeks of treatment with amphotericin B. The patient then received oral posaconazole, 800 mg/d, in divided doses for 6 months. Salvage treatment with the new azole antifungal posaconazole resulted in dramatic clinical improvement as early as 1 week after the initiation of therapy. Oral posaconazole continued through 24 weeks of treatment, with marked clinical, mycological, and radiological improvements and no adverse events. Here we review the medical literature on rhinocerebral mucormycosis, which is a rapidly progressive and often fatal infection. The treatment of choice is amphotericin B, which failed in our patient. Our case report suggests that posaconazole appears to be a well tolerated and effective salvage treatment option for rhinocerebral mucormycosis, including disseminated disease.
